Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Macrogenics Inc (MGNX)  
$4.48 0.39 (9.54%) as of 4:30 Mon 6/3


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 62,030,000
Market Cap: 277.89(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $3.31 - $21.47
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 350,000 2,394,399
Total Buy Value $0 $0 $1,722,425 $11,462,434
Total People Bought 0 0 1 2
Total Buy Transactions 0 0 2 11
Total Shares Sold 152,179 293,400 293,400 298,772
Total Sell Value $2,849,587 $4,995,238 $4,995,238 $5,027,631
Total People Sold 4 5 5 5
Total Sell Transactions 5 11 11 12
End Date 2024-03-03 2023-12-01 2023-06-02 2022-06-02

   
Records found: 319
  Page 12 of 13  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bonvini Ezio Senior VP, Research   •       –      –    2014-11-14 4 OE $0.71 $2,769 D/D 3,900 36,390     -
   Stein Kathryn E Senior VP, Prd Dev & Reg Aff   •       –      –    2014-11-14 4 AS $23.33 $541,513 D/D (23,211) 43,205     -
   Stein Kathryn E Senior VP, Prd Dev & Reg Aff   •       –      –    2014-11-14 4 OE $0.94 $21,818 D/D 23,211 66,416     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-11-13 4 AS $25.00 $250,000 D/D (10,000) 0     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-11-13 4 OE $0.94 $9,400 D/D 10,000 10,000     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-11-12 4 AS $23.00 $345,000 D/D (15,000) 0     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-11-12 4 OE $0.94 $9,400 D/D 10,000 15,000     -
   Saran Atul See remarks   •       –      –    2014-10-28 4 D $21.79 $18,848 D/D (865) 21,635     -
   Bonvini Ezio Senior VP, Research   •       –      –    2014-10-10 4 OE $0.71 $284 D/D 400 32,890     -
   Bonvini Ezio Senior VP, Research   •       –      –    2014-10-09 4 OE $0.71 $1,891 D/D 2,663 32,490     -
   Bonvini Ezio Senior VP, Research   •       –      –    2014-10-08 4 OE $0.94 $1,501 D/D 1,597 29,827     -
   Wigginton Jon Marc Sr V.P., Clinical   •       –      –    2014-10-01 4 AS $20.48 $102,400 D/D (5,000) 0     -
   Wigginton Jon Marc Sr V.P., Clinical   •       –      –    2014-10-01 4 OE $4.70 $23,500 D/D 5,000 5,000     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-09-02 4 AS $20.89 $173,721 D/D (8,316) 5,000     -
   Wigginton Jon Marc Senior VP, Clinical Dev.   •       –      –    2014-08-18 4 AS $20.52 $102,600 D/D (5,000) 0     -
   Wigginton Jon Marc Senior VP, Clinical Dev.   •       –      –    2014-08-18 4 OE $4.70 $23,500 D/D 5,000 5,000     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-06-30 4 AS $21.84 $174,720 D/D (8,000) 13,316     -
   Risser Eric Blasius VP, Business Development   •       –      –    2014-06-30 4 OE $0.94 $7,520 D/D 8,000 21,316     -
   Saran Atul See RemarksOfficer   •       –      –    2014-06-05 3 IO $0.00 $0 D/D 0 22,500     -
   Stein Kathryn E Senior VP, Prd Dev & Reg Aff   •       –      –    2014-05-29 4 S $19.75 $216,184 D/D (10,946) 43,205     -
   Stein Kathryn E Senior VP, Prd Dev & Reg Aff   •       –      –    2014-05-29 4 OE $0.71 $7,772 D/D 10,946 54,151     -
   Wigginton Jon Marc Sr VP, Clinical   •       –      –    2014-04-01 4 OE $4.70 $23,500 D/D 5,000 5,000     -
   Fust Matthew K Director   –       •      –    2014-03-05 3 IO $0.00 $0 D/D 0 500     -
   Hurwitz Edward Director   –       •      –    2014-02-18 4 S $36.50 $11,260,725 I/I (308,513) 1,704,996     -
   Oronsky Arnold L Director   –       •      –    2014-02-18 4 S $36.50 $7,300,000 I/I (200,000) 1,708,716     -
  319 Records found
  Previous  10  11  12  13   
  Page 12 of 13
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us